Fresenius Invests to Help Humacyte Develop Implantable Blood Vessels

Fresenius has invested an additional $25 million in Humacyte Inc, to help the implantable vessel company get market approval. The new vessels, which can be used to create and repair vascular accesses, are now being tested in a clinical trial for use in dialysis.

Read the full article » | Posted 09-14-2021

Related Articles

• Watch a 2-minute video of Dr. Brigitte Schiller describing a paper on nocturnal home HD Posted 08-21-2026
• The Quanta Dialysis System for home HD is the first FDA 510(k) approved machine that offers high (500 mL/min) dialysate flow Posted 08-21-2026
• The American Kidney Fund’s Kidney Action Week: Future of Kidney Care is September 8-10. Posted 08-21-2026
• On August 9, CMS published “Regulatory Alignment for Predictable and Immediate Device Coverage Pathway (CMS-3487-NC) Procedural Notice Inviting Comment.” Posted 08-21-2026